By Dr. SkinnyVIP · Published October 23, 2026 · Quotes link to CNBC's report of Walmart's announcement
With type 2 diabetes: starting in 2027, Walmart covers Ozempic and Mounjaro at no cost after a new prior authorization.
For weight loss: nothing changed. Walmart still does not cover Wegovy, Zepbound or other GLP-1s prescribed for weight loss.
“Walmart plans to cover more than 250 prescriptions, including some insulin, inhalers and GLP-1s for diabetes, at no cost to its employees.”
“Walmart will offer Novo's diabetes injection Ozempic and Eli Lilly's rival shot Mounjaro without charge for people with Type 2 diabetes after a new prior authorization.”
“But the company still does not cover GLP-1s from Novo and Lilly for the purpose of weight loss.”
CNBC reports Walmart employs about 1.6 million people in the U.S. For associates with type 2 diabetes this is one of the most generous GLP-1 benefits any large employer has announced. For associates who want a GLP-1 for weight management, the plan is the same as before: not covered.
Helps: associates and covered family members with a type 2 diabetes diagnosis, once the new prior authorization is approved: Ozempic and Mounjaro at $0 from 2027.
Does not help: associates without type 2 diabetes who want Wegovy or Zepbound for weight management. Walmart's plan, like those of most large employers (see the 2027 open-enrollment numbers), excludes that use.
Three questions for Walmart's benefits team, in writing: (1) Is there any weight-management benefit or reimbursement account in 2027? (2) What documentation does the new diabetes prior authorization require? (3) If I have prediabetes rather than type 2 diabetes, am I covered?
1. Ask your plan one question in writing. “Is there a continuation-of-therapy or medical-necessity exception for members already on a GLP-1, and what documentation does it need?” Many policies keep an exception for diabetes, cardiovascular risk reduction, sleep apnea or liver disease; a letter from your prescriber may qualify you.
2. Check the two public cash-pay routes for the brand-name drug. LillyDirect sells Zepbound to self-pay patients at published prices by dose ($299 to $699 a month for vials as of October 2026, per our Real-Price Index). If you are on Medicare Part D, the Medicare GLP-1 Bridge offers Wegovy or Zepbound for a $50 copay through December 2027 if you meet its criteria (details).
3. If neither fits, know the compounded option's real number. SkinnyVIP's clinician-prescribed compounded tirzepatide is $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose, with no membership, no subscription and no automatic renewal; you pay once per plan and nothing bills again unless you ask. If a licensed clinician does not prescribe, the medication cost is refunded in full. Compounded medications are not FDA-approved products; read how it works and what that means before deciding.
No. Walmart told CNBC on October 13, 2026 that it 'still does not cover GLP-1s from Novo and Lilly for the purpose of weight loss.' The 2027 change covers Ozempic and Mounjaro at no cost for type 2 diabetes, after prior authorization.
For associates with type 2 diabetes, yes, starting in 2027, per CNBC: Walmart will offer Ozempic and Mounjaro without charge after a new prior authorization, as part of covering more than 250 prescriptions at no cost.
In 2027, per CNBC. Confirm the exact plan-year date and the prior-authorization steps with Walmart's benefits team during open enrollment.
Ask the benefits team in writing whether any weight-management benefit or reimbursement account exists; the published announcement does not mention one. The cash-pay routes are LillyDirect's self-pay Zepbound prices, the Medicare GLP-1 Bridge if you are on Part D, or clinician-prescribed compounded tirzepatide.
$695 for a 3-month plan (about $232 a month) or $350 for one month, the same price at every dose, with no membership and nothing that renews. A licensed clinician reviews every request; prescription is not guaranteed. Compounded medications are not FDA-approved products.
Mounjaro and Zepbound are FDA-approved tirzepatide products made by Eli Lilly. Compounded tirzepatide is prepared by a licensed compounding pharmacy for an individual patient under physician supervision and is not FDA-approved; FDA does not review compounded drugs for safety, effectiveness or quality before marketing.
SkinnyVIP: $695 for 3 months (about $232/month) or $350 for one month, any dose. No membership. Nothing renews. You only pay if a licensed clinician approves treatment.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.